Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

Inclusion Criteria:

• Adult participants, male or female patients ≥ 18 years old at index date

• Participants must voluntarily give written informed consent form (ICF). Patientsmust read and fully understand the ICF

• Participants with confirmed diagnosis of RMS at index date, diagnosed by thetreating physician according to applicable clinical practice guidelines (currentlyMcDonald 2017 criteria), with high disease activity.

• Required historical data should be available: number of relapses in the 12 monthsprior to index date, DMTs taken prior to index date, date of MS diagnosis, and dataof at least 1 MRI prior to index date as specified in the drug Summary of ProductCharacteristics (SmPC)

• Fulfillment of the indication for treatment with cladribine tablets at index date,per standard of care in accordance with the local SmPC

• Meeting 1 of the following criteria:

• Prospective participants: Having been prescribed with cladribine tablets orhaving taken at least one dose of cladribine tablets, with enrollment dateprior to the second treatment week

• Retrospective participants: Having taken at least one dose of cladribinetablets, with enrollment date during or after the second treatment week but notmore than 3 years after the first dose of cladribine tablets

Exclusion Criteria:

• Contraindications to use of cladribine tablets according to the SmPC.

• Any participant who had the first dose of cladribine tablets more than 3 years priorto enrollment

• Any participant who is pregnant or plans to breast-feed while taking cladribinetablets, or any patient who or whose partner plans to become pregnant in Year 1 orwithin 6 months after the last dose in Year 2, or any participants who is unwillingor unable to use contraception per the SmPC

• Have participated or participating in an interventional study since cladribinetablet initiation, in which participant assessment and/or treatment may be dictatedby a protocol

• Participants who, at the discretion of the Investigator, will not be able to providereliable information for the study